PAPER Xu Y, Schnorrer P, Proietto A, Kowalski G, Febbraio MA, Acha-Orbea H, Dickins RA, Villadangos JA
SEARCH RESULTS
331159 RESULTS
PAPER Gravius A, Laszy J, Pietraszek M, Sághy K, Nagel J, Chambon C, Wegener N, Valastro B, Danysz W, Gyertyán I
Effects of 5-HT6 antagonists, Ro-4368554 and SB-258585, in tests used for the detection of cognitive enhancement and antipsychotic-like activity.
Behav Pharmacol. 2011 Apr;22(2):122-35. PubMed: 21301322PAPER Hartlage-Rübsamen M, Morawski M, Waniek A, Jäger C, Zeitschel U, Koch B, Cynis H, Schilling S, Schliebs R, Demuth HU, Rossner S
Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Aβ deposits in hippocampus via distinct cellular mechanisms.
Acta Neuropathol. 2011 Jun;121(6):705-19. PubMed: 21301857PAPER Bai Y, Tohda C, Zhu S, Hattori M, Komatsu K
Active components from Siberian ginseng (Eleutherococcus senticosus) for protection of amyloid β(25-35)-induced neuritic atrophy in cultured rat cortical neurons.
J Nat Med. 2011 Jul;65(3-4):417-23. PubMed: 21301979PAPER Soria-Urios G, Duque P, García-Moreno JM
[Music and brain: neuroscientific foundations and musical disorders].
Rev Neurol. 2011 Jan 1;52(1):45-55. PubMed: 21246493PAPER Koechlin C
[Memory Bistros to maintain social ties for Alzheimer patients and their carers].
Soins Gerontol. 2010 Nov-Dec;(86):27-8. PubMed: 21298963PAPER Voineskos AN, Lerch JP, Felsky D, Shaikh S, Rajji TK, Miranda D, Lobaugh NJ, Mulsant BH, Pollock BG, Kennedy JL
The brain-derived neurotrophic factor Val66Met polymorphism and prediction of neural risk for Alzheimer disease.
Arch Gen Psychiatry. 2011 Feb;68(2):198-206. PubMed: 21300947PAPER Schjeide BM, Schnack C, Lambert JC, Lill CM, Kirchheiner J, Tumani H, Otto M, Tanzi RE, Lehrach H, Amouyel P, von Arnim CA, Bertram L
The role of clusterin, complement receptor 1, and phosphatidylinositol binding clathrin assembly protein in Alzheimer disease risk and cerebrospinal fluid biomarker levels.
Arch Gen Psychiatry. 2011 Feb;68(2):207-13. PubMed: 21300948PAPER Kim SY, Karlawish JH, Kim HM, Wall IF, Bozoki AC, Appelbaum PS
Preservation of the capacity to appoint a proxy decision maker: implications for dementia research.
Arch Gen Psychiatry. 2011 Feb;68(2):214-20. PubMed: 21300949Sarah Ellwood
Robert Moir on Crystal structure of the amyloid-β p3 fragment provides a model for oligomer formation in Alzheimer's disease.
COMMENT The study describes an elegant tool for what has been a frustrating problem. Of particular interest to us, this study shows that Aβ dimers have striking structural similarities to the dimeric forms of the antimicrobial peptides human NP2, horseshoe crab t
Helen Cunningham on Miami: Is Human Amyloid Imaging Ready for Clinical Trials?
COMMENT Re: "It is generally accepted that about every fifth person diagnosed as having AD turns out after death not to have had amyloid pathology. If AD is defined by its signature pathology, Feldman said, then these 20 percent of cases should not be called
Jose Joaquin Merino on Genetics of FTD: New Gene, PGRN Variety, and a Bit of FUS
COMMENT We have evidence for a role of fractalkine in the pathophysiology of frontotemporal dementia in progranulin (PGRN) mutation carriers. In addition, PGRN upregulates several cell adhesion molecules in cortical neurons at seven days in vitro, and promotes ne
Carlo Condello on CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models.
COMMENT We would like to point out our recently published paper, "CX3CR1 in microglia regulates brain amyloid deposition through selective protofibrillar amyloid-β phagocytosis" (Liu et al., 2010). Similar to Lee et al., we also observe a reduction in f